News | July 24, 2021
Lonza reports strong momentum in H1 2021
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Dr. Reddy's has the rights to distribute 250mn doses in India
The facility is expected to be completed in 2024
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Subscribe To Our Newsletter & Stay Updated
